AARDEX Group

Decentralized Clinical Trials

GLP-1 dose. Patient adherence.

One size fails all? The weight of evidence for personalized dosing in oral GLP-1 therapies

In recent years, the pharmaceutical industry has borne witness to the meteoric rise of glucagon-like peptide-1 receptor agonist (GLP-1) therapies. Having fast become established as a potentially life-changing treatment for Type 2 diabetes and obesity, emerging evidence of the cardio and … Read More

FDA Issues Proposed Guidance for the use of Digital Health Technology in Clinical Investigations

FDA Issues Proposed Guidance for the use of Digital Health Technology in Clinical Investigations

In recent years, a multitude of Digital Health Technologies (DHTs) have emerged, many with the ability to solve some of the biggest problems in clinical trials. However, uptake has been slow.  Now, proposed new Food and Drug Administration (FDA) guidelines … Read More

Adherence in Decentralized Clinical Trials

Addressing Medication Adherence in Decentralized Clinical Trials

Adherence monitoring can minimize variability and maximize engagement in DCTs Decentralized clinical trials (DCT) are growing in popularity, thanks to their ability to tear down many of the long-standing barriers to robust medical research. And while this new model has … Read More